Journals / Van Tıp Dergisi / 2012 / Cilt: 19 - Sayı: 1

Can the fetal nuchal translucency be determined before the eleventh week of the pregnancy when it is routinely measured? A case report, and theories of fetal nuchal translucency

Fetal Ense Kalınlığı rutin ölçüm tarihi olan 11. Gebelik haftasından öncede tespit edilebilir mi? Olgu Sunumu ve Fetal Ense Kalınlığı Teorileri.

Pages
42–45
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, when excess NT in early gestation weeks(<11 weeks) is observed one should think Turner Syndrome. as the in of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:First trimester nuchal translucency (NT) is the most effective screening strategy for Down syndrome well as other aneuploidy and anomalies.
📊
Key Findings & Data:Current guidelines for the measurement of nuchal translucency recommend that the measurement should be taken between 11 and 14 weeks’ gestation when the fetal crown–rump length is between 45 and 84 mm.
💡
Conclusion & Impact:Therefore, when excess NT in early gestation weeks(<11 weeks) is observed one should think Turner Syndrome. as the in of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

First trimester nuchal translucency (NT) is the most effective screening strategy for Down syndrome well as other aneuploidy and anomalies. Current guidelines for the measurement of nuchal translucency recommend that the measurement should be taken between 11 and 14 weeks’ gestation when the fetal crown–rump length is between 45 and 84 mm. Cardinal proposed mechanisms for increase in NT thickness include altered composition of the extracellular matrix, abnormalities of the heart and great arteries, and disturbed or delayed lymphatic development. Increased NT measurement in early pregnancy may be associated with distended jugular sacs and suggest a disturbancelymphangiogenesis as seen in Turner syndrome. Therefore, when excess NT in early gestation weeks(<11 weeks) is observed one should think Turner Syndrome. as the in of

Özet

İlk trimester ense kalınlığı (NT) Down Sendromu’nun yanı sıra diğer anöploidiler ve anomaliler için deetkili tarama stratejisidir. Ense kalınlığı ölçümü için güncel kılavuzlar, fetal baş-popo uzunluğunun 45 vemm arasında olduğu 11 ile 14. gebelik haftaları arasında ölçüm yapılmasını önermektedir. NT kalınlığı artışında ileri sürülen en önemli mekanizmalar; ekstraselüler matriksin kompoziyonunun değişmesi, kalpbüyük arter anomalileri ve bozuk veya gecikmiş lenfatik gelişimdir. Erken gebelikte artmış NT ölçümü, distandü juguler keseler ile ilişkili olabilir ve Turner Sendromu’ndaki gibi lenfanjiogenetik bir bozukluk olduğunu düşündürmektedir. Bu yüzden, erken gestasyonel haftada (<11 hafta) görülen aşırı NT ölçümü Turner Sendromu’nu düşündürmelidir. en 84 ve

🔖

Cite This Article

ALANBAY, İ., ÇOKSÜER, H., ERCAN, C. M., EVREN, A. G., KARAŞAHİN, K. E., KESKİN, U., ERGÜN, A. (2012). Can the fetal nuchal translucency be determined before the eleventh week of the pregnancy when it is routinely measured? A case report, and theories of fetal nuchal translucency. Van Tıp Dergisi, Cilt: 19 - Sayı: 1, 42–45. https://ajindex.com/articles/334817

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Nicolaides KH, Azar G, Byrne D, Mansur Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992; 304:867- 869. Snijders RJM, Noble P, Sebire NJ, Souka Nicolaides KH. UK multicentre project assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352:343-346.
  2. Souka AP, Snijders RJM, Novakov A, Soares W, Nicolaides KH. Defects and syndromes chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation. Ultrasound Obstet Gynecol 1998;11:391-400. Souka AP, von Kaisenberg CS, Hyett Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am Obstet Gynecol 2005; 192:1005-1021.
  3. Nicolaides KH, Heath V, Cicero S. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 2002; 22:308-315. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191:45-67. Haak MC, van Vugt JMG. Pathophysiology of increased nuchal translucency: a review of the literature. Hum Reprod Update 2003; 9:175- 184. Sheppard C, Platt LD. Nuchal translucency and first trimester risk assessment: a systematic review. Ultrasound Q 2007; 23:107-116. Chih-Ping Chen Pathophysiology of increased of fetal nuchal translucency thickness. Taiwan J Obstet Gynecol 2010; 49:133-138. 0. Von Kaisenberg C, Brand-Saberi B, Jonat W, et al. Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses. Prenat Neonatal Med 1999; 32:193- 199. Bekker MN, van den Akker NM, de Mooij YM, Bartelings MM, van Vugt JM, Gittenberger-de Groot AC. Jugular lymphatic maldevelopment in Turner syndrome and trisomy 21: different anomalies leading to nuchal edema. Reprod Sci 2008; 15:295-304. von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B. Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency. Hum Reprod 2003; 18:2544- 2561. Geerkens C, Vetter U, Just W, et al. The X- chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous gene. Hum Genet 1995; 96:44-52.
  4. Hyett J, Perdu M, Sharland GK, Snijders RJM, Nicolaides KH. Increased nuchal translucency at 10–14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol